Patent Grant
11566268
The invention relates to a process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. In particular, the invention relates to a process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate from a single starting material feedstock of poly-(R)-3-hydroxybutyrate.
Ketone bodies are chemical compounds which are produced by the liver from fatty acids released from adipose tissue. Ketone bodies themselves can be used as a source of energy in most tissues of the body. The intake of compounds that boost the levels of ketone bodies in the blood can lead to various clinical benefits, including an enhancement of physical and cognitive performance and the treatment of cardiovascular conditions, diabetes, neurodegenerative diseases and epilepsy. Ketone bodies include (R)-3-hydroxybutyrate and acetoacetate.
WO2004/108740 discloses that ketone bodies may be administered directly to achieve elevated levels of ketone bodies in a subject. However, direct administration of the compounds is unpractical and potentially dangerous. For example, direct administration of either (R)-3-hydroxybutyrate or acetoacetate in its free acid form can result in significant acidosis following rapid absorption from the gastrointestinal tract. Administration of the sodium salt of these compounds in unregulated amounts is also unsuitable due to a potentially dangerous sodium overload that could accompany administration of therapeutically relevant amounts of the compounds. Examples of the derivatives include esters, for instance esters derived from a variety of alcohols and oligomers of (R)-3-hydroxybutyrate.
WO2010021766 discloses that one particular enantiomer of one particular ester of 3-hydroxybutyrate is an effective and palatable precursor to the ketone body (R)-3-hydroxybutyrate. Thus WO2010021766 discloses 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (R)-3-hydroxybutyl (R)-3-hydroxybutyrate.
Various synthetic approaches have been developed for the production of this stereoisomer. Methods are known for producing hydroxybutyrate from poly-(R)-3-hydroxybutyrate but involve a large number of steps and are complex. Other synthetic approaches have been attempted but have various technical and commercial drawbacks including low yields, the production of impure product, impracticability on a large scale and cost.
WO2010/120300 discloses various methods of a producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate involving enantioselective reduction of a compound of formula I, II or III.
WO2010/120300 also discloses a process involving treating HOCH2CH2COCH3 with a diketene of formula VI in WO2010120300, CH2═C(CH2)—O—C═O and subjecting the reaction to enantioselective reduction. Further processes involving treating butane-1,3-diol with the ketene VI with enantioselective reduction and a process starting from 4-hydroxybutanone are also disclosed. The enantioselective reduction is carried out using a ketoreductase or alcohol dehydrogenase.
Whilst effective at producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate these starting materials may be costly and higher rates of reaction may be desirable. There remains a need to be able to produce (R)-3-hydroxybutyl (R)-3-hydroxybutyrate at higher volumes and to improve the economics of production.
We have now found that these problems may be addressed by subjecting poly-(R)-3-hydroxybutyrate, a relatively low cost starting material, to a process that involves transesterification divides the starting material or feedstock into two portions or streams, producing a reduced intermediate from a first portion or stream, which is then reacted with a second portion or stream to provide (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. In a first aspect the invention provides a process for the production of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate comprising:
The process allows industrial scale production of enantiomerically enriched monoester of (R)-3-hydroxybutyric acid and (R)-1,3-butanediol from bulk poly-(R)-3-hydroxybutyrate which is commercially available in large scale and acceptable cost, for example by fermentation of corn starch or sugar cane.
The term “enriched”, as employed herein, means that the level of the enriching isomer is higher than the level at which that isomer would be present in a racemic mixture. Where a percentage enrichment is referred to, the enriching isomer constitutes that molar percentage of the total 3-hydroxybutyl 3-hydroxybutyrate product present.
Preferably enantiomeric purity is measured using chiral high performance liquid chomatography (chiral HPLC). Measurements are typically made against the corresponding racemic mixture. Alternatively, chiral gas chomatography (chiral GC) may be used reliably. Accordingly, where a percentage enrichment is referred to herein, the percentage enrichment is typically that measured by chiral HPLC or by chiral GC. Preferably, the percentage enrichment is that measured by chiral HPLC. Usually, the enzyme employed is one which is capable of reducing said compound of formula (II), (III) or (IV) to produce 3-hydroxybutyl 3-hydroxybutyrate which is enantiomerically enriched to at least 95%, for instance to at least 97%, to at least 98%, or to at least 99%, with respect to (R)-3-hydroxybutyl(R)-3hydroxybutyrate.
The process may be continuous or batch. Advantageously, the invention enables a high throughput industrial production of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate from poly-(R)-3-hydroxybutyrate which may be obtained from corn starch.
Preferably, the poly-(R)-3-hydroxybutyrate feedstock is provided from a single feedstock by fermentation of corn starch with microorganisms.
The poly-(R)-3-hydroxybutyrate feedstock may be transesterified in step i) using any suitable alcohol which allows the formed ester to be reduced to (R)-1,3-butanediol. Suitably a dihydric or trihydric alcohol is employed but preferably the alcohol is monohydric, for example a C1-6 alcohol. Where (R)-3-hydroxybutyl (R)-3-hydroxybutyrate is for consumption for example as a food or nutritional supplement, the alcohol is suitably ethanol as this is more acceptable for consumption than other alcohols.
Suitably, the alcohol is present in sufficient quantity that poly-(R)-3-hydroxybutyrate moieties may be esterified. Preferably the weight ratio of alcohol to poly-(R)-3-hydroxybutyrate is from 1:1 to 10:1, more preferably from 2:1 to 6:1.
The transesterification in step i) is suitably carried out in acidic conditions. Preferably, the reaction mixture comprises an acid catalyst. The acid may be organic or inorganic and is preferably a mineral acid, for example sulphuric acid. The catalyst may be solid as desired.
Suitably the transesterification is carried out at elevated temperature, preferably greater than 50° C., greater than 90° C. and desirably not more than 150° C. Elevated pressure may be employed. Suitably, the transesterification is carried out for sufficient time to affect transesterification to an economically acceptable degree having regard to the temperature, catalyst and alcohol employed. Preferably, the transesterification step is carried out for at least 1 hour, more preferably at least 10 hours, and especially 15 to 30 hours, for example 20 hours, 22 hours and 24 hours.
The product of the transesterification reaction may then be treated by one or more optional steps including filtering, purification, for example by distillation and neutralisation for example by the addition of base for example hydroxide, bicarbonate and acetate, particularly calcium hydroxide or sodium bicarbonate to neutralise the acid present.
Suitably, the ester of (R)-3-hydroxybutyrate is separated from the reaction mixture by removal of alcohol and optionally by-products of the reaction. The separation may be carried out in multiple stages as desired. In a preferred embodiment, the ester is separated and purified from the alcohol and reaction by-products. The ester may be separated from unreacted alcohol and other undesired materials, for example alkyl crotonate by separation of the liquid phase, for example by distillation of the alcohol and alkyl crotonate. The alcohol and by-products may be removed by multiple distillations, suitably at atmospheric pressure and at a temperature above the boiling point of the alcohol, for example greater than 80° C., greater than 110° C. for example at a temperature of 110 to 150° C. The ester of (R)-3-hydroxybutyrate is then suitably separated to provide a first portion which is subjected to a reduction reaction. The reduction in step ii) may be a hydride transfer reduction, hydrogenation, hydrosilylation followed by silyl ether hydrolysis. Preferably the reduction is carried out with any suitable reducing agent for reducing an ketoester. The reducing agent may be organic or inorganic. The reduction step may be mediated by an enzyme, for example a ketoreductase (KRED) or an alcohol dehydrogenase (ADH), and may be naturally occurring or commercially available, for example as described in WO2010/120300.
The reducing agent may comprise hydrogen and a hydrogenation catalyst may be employed, for example Raney nickel, desirably employed at elevated pressure and temperature and catalysts comprising platinum, palladium, rhodium, iridium or ruthenium. Preferably the reducing agent employs a hydride transfer reagent. Examples of suitable reducing agents include complex metal hydrides for example, lithium aluminium hydride, lithium tetrahydridoaluminate, sodium bis (2-methoxyethoxy) aluminium hydride, sodium borohydride, nickel borohydride, other inorganic reducing agents, for example, sodium hydrosulphite, sodium tetrahydroborate and ruthenium hydrogenation catalysts known in the art, for example ruthenium hydride and rhodium hydrogenation catalysts known in the art, aluminium triisopropoxide, and organic reducing agents including a chiral borane, for example 2,5-dimethylborolane, borontrihydride:tetrahydrofuran caticholborane, and enzymes and cofactors, for example nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH). As desired a cofactor recycling system is suitably employed.
The reducing step is suitably carried out under reducing conditions. A solvent may be employed. The solvent may be anhydrous, for example diethyl ether or tetrahydrofuran, or may be carried out in polar protic solvent, for example water, alcohol and basic aqueous media, depending upon the reducing agent.
Preferably, the reducing step is carried out in aqueous solution and a moderately strong reducing agent is employed so as to ensure retention of the desired stereochemistry. Desirably, the temperature of the reducing step is controlled to avoid significant temperature rise, and is desirably carried out at a temperature below standard temperature, desirably under 10° C., for example −5 to 3 C.
Suitably, the reducing agent is contacted with the first portion slowly to avoid undue temperature rise. The reducing agent and first portion are suitably allowed to react over an extended period of time, for example at least 30 minute, preferably at least 1 hour, more preferably 1 to 20 hours, especially 4 to 10 hours. Upon completion of the reduction reaction to the desired degree, the reaction may be quenched by addition of a quenching agent, for example by addition of acid, for example sulphuric acid and allowed to stand for a period of time, for example at least 1 hour, preferably 1 to 20 hours, for example overnight. Thereafter, the reaction mixture may be contacted with a removal agent, for example hydroxide and especially calcium hydroxide to remove salts of the reducing agent and quenching agent.
The butanediol produced from the first portion is then contacted with the second portion of the ester of (R)3-hydroxybutanoate.
The transesterification is suitably carried out in the presence of a transesterification catalyst, for example an enzyme, acid or base. Suitable examples of enzymes include lipase, examples of suitable acids include mineral acids for example sulphuric acid and hydrochloric acid, examples of suitable bases include alkali metal hydroxides and alkali metal alkoxides.
Preferably, the transesterification reaction between the second portion and (R)-1,3-butanediol is carried out at elevated temperature, for example from 30 to 150° C., particularly 40 to 100° C.
This transesterification process may be carried out in a batch or continuous process.
Suitably the transesterification process is carried out for at least 1 hour, preferably 1 to 20 hours, for example 5 to 10 hours. Upon completion of the reaction to the desired degree, the product of the reaction may then be subjected to further treatment to remove catalyst, unreacted starting materials and by-products, for example by filtering, distillation or the like.
The invention will be illustrated by the following non-limiting examples.
A 5 gallon Parr reactor is charged with 12.5 L (10 kg) absolute ethanol and 2.5 kg poly (R)-3-hydroxybutanoate (Biocycle, Fazenda de Pedra, c Postal 02 CEP 14158-00, Serenaa, S.P. Brazil) and stirred for 2-5 min to complete mixing after which 0.1 L concentrated sulfuric acid is added slowly to the mixture. The mixture is heated with a 300° C./h ramp to 110° C. and the reactor held in soak mode for a total run time is 22 h. The unit is cooled to about 30° C. using chilled water. After the temperature has fallen below 60° C., the digester is vented and purged with nitrogen to remove formed ether. An amount of base, equal to the equivalents of acid is added to the crude digest with stirring to neutralize the acid. Stirring is continued about 16 h after which the stirring is stopped and the solids left to settle. The liquid phase is siphoned off into a wiped film distillation apparatus and distilled in phases to remove first the ethanol and ethyl crotonate (a side product), and then the ethyl (R)-3-hydroxybutyrate. Ethanol/ethyl crotonate is distilled off over 3 passes generally at atmospheric pressure and band heater and pump flow rates of 120 & 5 L/h, 120 & 3 L/h and 140 & 3 L/h respectively. The ethyl (R) 3-hydroxybutyrate is distilled at 10 mmHg, band heater=88 and feed rate 4 L/h. The primary chiller is set to 5° C. and the secondary chiller at −1° C. for all distillations. The trap is charged with dry ice and either acetone or IPA. When collecting the ethyl (R) 3-hydroxybutyrate, the residue from the first pass is recycled through the still to recover more product. The ethyl-(R)-3-hydroxybutyrate is assayed by GC-MS and NMR for purity.
A heavy duty stainless steel stock pot is charged with 12 L water and a portion of (3.49 L) ethyl (R) 3-hydroxybutyrate. Both water and ester were previously chilled to 4° C. for at least 24 h. The stock pot is surrounded by ice, gassed with nitrogen and stirred. After about 1 h, 1 Kg sodium borohydride is added in small aliquots to order to minimize temperature gain. Borohydride addition takes about 1 h and the temperature should be kept below 20° C. during the NaBH4 addition. About 5 h after borohydride addition the reaction is quenched by slowly adding 745 ml concentrated sulfuric acid. The mixture is allowed to stand, with stirring overnight and the temperature rise to room temperature. The mixture is filtered, the filtrate heated to 90° C. and neutralized* by adding calcium hydroxide with stirring. After 2 hours mixture is cooled and filtered and the filtrate ionic strength reduced using ion exchange resins after which the solution is placed on a Buchi Rotovap and the bulk of the water removed. This leaves a viscous liquid assaying to >10 M (R) 1,3-butanediol and containing 5-10% water. Remaining water is removed by nitrogen purge or distillation. The purity is checked by enzymatic assay, GC-MS and NMR.
A solution is prepared by combining and mixing 600 ml of (R) 1,3-butanediol and 1200 ml of ethyl (R)-3-hydroxybutanoate in a stainless steel pan. A nylon mesh “tea bag” containing lipase is laid in the solution and the pan is placed on a heating pad set to 40° C. The “tea bag” is sewn with lanes to keep the enzyme dispersed. The reaction is carried out under nitrogen with agitation. After 6 h the reaction is stopped by removing the “tea bag” and collecting the solution. The solution is passed through a filter to remove any enzyme resin “fines” and collected. Once enough crude solution has been collected the solution is distilled sequentially to first degas and remove any remaining ethanol, then to remove ethyl (R)-3-hydroxybutanoate, (R) 1,3-butanediol and finally to collect the desired pure ketone ester, (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Recovered ethyl (R)-3-hydroxybutanoate and (I) 1,3-butanediol are recycled in subsequent transesterification experiments. Crude solutions and still fractions are analyzed by GC-MS.
The present application was made with government support under Grant No. W911NF-05-1-0479 awarded by ARMY/ARO. The government has certain rights in this invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3984566 | Van Scott et al. | Oct 1976 | A |
| 4380549 | Van Scott et al. | Apr 1983 | A |
| 5112865 | Nichels et al. | May 1992 | A |
| 5281691 | Hubbs et al. | Jan 1994 | A |
| 5468507 | Czap | Nov 1995 | A |
| 5654266 | Chen et al. | Aug 1997 | A |
| 5665831 | Neuenschwander et al. | Sep 1997 | A |
| 5693850 | Birkhahn et al. | Dec 1997 | A |
| 6126953 | Costa et al. | Oct 2000 | A |
| 6136862 | Hiraide et al. | Oct 2000 | A |
| 6207856 | Veech | Mar 2001 | B1 |
| 6268167 | Wild et al. | Jul 2001 | B1 |
| 6316038 | Veech | Nov 2001 | B1 |
| 6323237 | Veech | Nov 2001 | B1 |
| 6380244 | Martin et al. | Apr 2002 | B2 |
| 6544960 | Eldred et al. | Apr 2003 | B1 |
| 6939570 | Snow et al. | Sep 2005 | B1 |
| 7351736 | Veech | Apr 2008 | B2 |
| 7947736 | Gross | May 2011 | B2 |
| 8101653 | Veech | Jan 2012 | B2 |
| 8642654 | Clarke et al. | Feb 2014 | B2 |
| 9034613 | Robertson et al. | May 2015 | B2 |
| 9211275 | Clarke et al. | Dec 2015 | B2 |
| 9579302 | Veech et al. | Feb 2017 | B2 |
| 20010014696 | Veech et al. | Aug 2001 | A1 |
| 20010041741 | Sole et al. | Nov 2001 | A1 |
| 20010047008 | Baraldi | Nov 2001 | A1 |
| 20020006959 | Henderson | Jan 2002 | A1 |
| 20020013339 | Martin et al. | Jan 2002 | A1 |
| 20020035231 | Whitehouse et al. | Mar 2002 | A1 |
| 20020098557 | Muller | Jul 2002 | A1 |
| 20030022937 | Veech | Jan 2003 | A1 |
| 20030158274 | Zhong et al. | Aug 2003 | A1 |
| 20040006263 | Anderson et al. | Jan 2004 | A1 |
| 20040063661 | Linnane | Apr 2004 | A1 |
| 20040171671 | Veech | Sep 2004 | A1 |
| 20040266872 | Veech | Dec 2004 | A1 |
| 20050129783 | McCleary et al. | Jun 2005 | A1 |
| 20050165318 | Brodnick et al. | Jul 2005 | A1 |
| 20050181275 | Jang | Aug 2005 | A1 |
| 20050182235 | Zhong et al. | Aug 2005 | A1 |
| 20060078596 | Clarke et al. | Apr 2006 | A1 |
| 20060280721 | Veech et al. | Dec 2006 | A1 |
| 20070179197 | Henderson et al. | Aug 2007 | A1 |
| 20080287372 | Henderson | Nov 2008 | A1 |
| 20090197952 | Hashim et al. | Aug 2009 | A1 |
| 20090253781 | Veech | Oct 2009 | A1 |
| 20100298294 | Clarke et al. | Nov 2010 | A1 |
| 20110237666 | Clarke et al. | Sep 2011 | A1 |
| 20120064611 | Robertson et al. | Mar 2012 | A1 |
| 20120071548 | Veech | Mar 2012 | A1 |
| 20120213835 | Neas et al. | Aug 2012 | A1 |
| 20130102663 | Clarke et al. | Apr 2013 | A1 |
| 20140194509 | Clarke et al. | Jul 2014 | A1 |
| 20140308719 | Clarke et al. | Oct 2014 | A1 |
| 20150065571 | Clarke et al. | Mar 2015 | A1 |
| 20150164855 | Clarke et al. | Jun 2015 | A1 |
| 20150250755 | Veech et al. | Sep 2015 | A1 |
| 20160030314 | Clarke et al. | Feb 2016 | A1 |
| 20160193173 | Clarke et al. | Jul 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 1330307 | Jun 1994 | CA |
| 2173270 | Oct 1996 | CA |
| 1483355 | Sep 2002 | CN |
| 1552315 | Dec 2004 | CN |
| 1141293 | Dec 1962 | DE |
| 20205184 | Dec 2002 | DE |
| 0 266 217 | May 1988 | EP |
| 0 537 113 | Apr 1993 | EP |
| 0552896 | Jul 1993 | EP |
| 0 721 740 | Jul 1996 | EP |
| 0816316 | Jan 1998 | EP |
| 1568780 | Aug 2005 | EP |
| 1809235 | Jul 2007 | EP |
| 2 875 812 | May 2015 | EP |
| 1524611 | Sep 1978 | GB |
| 0312603.4 | Jun 2003 | GB |
| 0313760.1 | Jun 2003 | GB |
| 2511941 | Sep 2014 | GB |
| S54-138126 | Oct 1979 | JP |
| S63-112998 | May 1988 | JP |
| H01-160917 | Jun 1989 | JP |
| H03-083950 | Apr 1991 | JP |
| 04112825 | Apr 1992 | JP |
| H07-76513 | Mar 1995 | JP |
| H08-191664 | Jul 1996 | JP |
| H01-95730 | Apr 1998 | JP |
| 10175855 | Jun 1998 | JP |
| H10-265378 | Oct 1998 | JP |
| H10-313819 | Dec 1998 | JP |
| 2001-515510 | Sep 2001 | JP |
| 2005-247821 | Sep 2005 | JP |
| 2008-513017 | May 2008 | JP |
| 2008127369 | Jun 2008 | JP |
| 2008-263825 | Nov 2008 | JP |
| 2009532496 | Sep 2009 | JP |
| 2012500264 | Jan 2012 | JP |
| 507322 | Mar 1976 | SU |
| 198703806 | Jul 1987 | WO |
| 199509144 | Apr 1995 | WO |
| 1998041201 | Sep 1998 | WO |
| 1998041200 | Sep 1998 | WO |
| 1999024451 | May 1999 | WO |
| 200004895 | Feb 2000 | WO |
| 200015216 | Mar 2000 | WO |
| 200113877 | Mar 2001 | WO |
| 200151645 | Jul 2001 | WO |
| 2002006368 | Jan 2002 | WO |
| 2003012417 | Feb 2003 | WO |
| 2003056319 | Jul 2003 | WO |
| 2003097860 | Nov 2003 | WO |
| 2004105742 | Dec 2004 | WO |
| 2004108740 | Dec 2004 | WO |
| 2006020137 | Feb 2006 | WO |
| 2006031941 | Mar 2006 | WO |
| 2006061624 | Jun 2006 | WO |
| 2006070337 | Jul 2006 | WO |
| 2007001883 | Jan 2007 | WO |
| 2007063037 | Jun 2007 | WO |
| 2007115282 | Oct 2007 | WO |
| 2007115934 | Oct 2007 | WO |
| 2008074473 | Jun 2008 | WO |
| 2008119032 | Oct 2008 | WO |
| 2008140828 | Nov 2008 | WO |
| 2009023357 | Feb 2009 | WO |
| 2009089144 | Jul 2009 | WO |
| 2010021766 | Feb 2010 | WO |
| 2010120300 | Oct 2010 | WO |
| 2011101171 | Aug 2011 | WO |
| 2011121540 | Oct 2011 | WO |
| 2012113415 | Aug 2012 | WO |
| 2013150153 | Oct 2013 | WO |
| 2014071389 | May 2014 | WO |
| 2014153416 | Sep 2014 | WO |
| Entry |
|---|
| O'Neil et al. Tetrahedron Asymmetry (1994) 5(1): 117-118. |
| Silva et al. J. Ind. Microbiol. Biotechnol. (2004) 31: 245-254. |
| Seebach et al. Organic Syntheses, Coll. (1998) 9: p. 483; vol. 71 (1993): p. 39. |
| Casey et al. Adv. Practical Organic Chemistry (1990) (Blackie: Glasgow and London) pp. 158-160. |
| Salehizadeh et al. Biotechnol. Advances (2004) 22: 261-279. |
| Kashiwaya et al. J. Biol. Chem. (2010) 285(34) 25950-29596 (Year: 2010). |
| Chaikin et al. J. Am. Chem. Soc. (1949) 71(1): 122-125 (Year: 1949). |
| Kotz and P{urcell“Chemistry and Chemical Reactivity” Second edition, 1991 (Saunders College Publishing: fort Worth) pp. 113-114 (Year: 1991). |
| English translation of DE 1141293B (1962) downloaded from the EPO on Jun. 3, 3021 (Year: 1962). |
| Machine translation of CN 1397577 published Feb. 15, 2003 dowloaded from IP.com Dec. 22, 2021 (Year: 2003). |
| Sharma et al. J. Molec. Catalysis B: Enzymatic (2000) 10: 531-534 (Year: 2000). |
| Linko J. Am. Oil Chem. Soc (1995) 72(11): 1293-1299 (Year: 1995). |
| Hoeng et al. Biotechnol. Bioengineer. (2000) 69(4): 379-376 (Year: 2000). |
| Buteau (2009) “Obviousness of Enantiomers over Prior Art Racemates,” The Journal of High Technology Law. L22. pp. 42-49. |
| Desrochers et al. (1992) “Metabolism of R and S-1,3-butanediol in perfused livers from meal-fed and starved rats,” Biochem. J. 285:647-653. |
| Desrochers et al. (1995) “Metabolism of (R,S)-1,3-butanediol acetoacetate esters, potential parenteral and enteral nutrients in conscious pigs,” Am. J. Physiol. 268:E660-667. |
| Desrochers et al. (1995) “R, S-1, 3-butanediol acetoacetate esters, potential alternates to lipid emulsions for total parenteral nutrition,” Journal of Nutritional Biochemistry. 6(2):111-118. |
| Edegger et al. (2006) “Regio- and Stereoselective Reduction of Diketones and Oxidation of Diols by Biocatalytic Hydrogen Transfer,” Eur. J. Org. Chem. 2006(8):1904-1909. |
| Goldbort et al. (1976) “Butanediols: Selection, open field activity, and NAD reduction by liver extracts in inbred mouse strains,” Pharmacology Biochemistry and Behaviour. 5(3):263-268. |
| Kalaitzakis et al. (2005) “Highly Stereoselective Reductions of α-Alkyl-1,3-diketones and α-Alkyl-β-keto Esters Catalyzed by Isolated NADPH-Dependent Ketoreductases,” Org. Lett. 7(22):4799-4801. |
| Malloy et al. (2006) “Drug Therapy of Dyslipidemia,” In; Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th Ed. McGraw-Hill. New York, New York. pp. 948-953. |
| Puchowicz et al. (2000) “Dog model of therapeutic ketosis induced by oral administration of R,S-1,3-butanediol diacetoacetate,” J. Nutr. Biochem. 11:281-287. |
| Shaw et al. (1984) “Influence of beta-hydroxybutyrate infusion on glucose and free fatty acid metabolism in docs,” Am. J. Phys. 247:E756-764. |
| Tobin et al. (1972) “Effect of 1,3-Butanediol and Propionic Acid on Blood Ketones, Lipids and Metal Ions in Rats,” Journal of Nutrition. 102(8):1001-1008. |
| Turner et al. (1999) “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49),” The Journal of the American Medical Association. 281(21):2005-2012. |
| Zhu et al. (2006) “A recombinant ketoreductase tool-box. Assessing the substrate selectivity and stereoselectivity toward the reduction of β-ketoesters,” Tetrahedron. 62:901-905. |
| International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2009/030095, dated Jul. 6, 2010. |
| International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2009/040773, dated Oct. 18, 2011. |
| International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/EP2011/000833, dated Jun. 22, 2011. |
| International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/US2004/018016, dated Apr. 15, 2005. |
| International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/US2009/030095, dated Feb. 23, 2009. |
| International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/US2009/040766, dated Aug. 6, 2009. |
| International Search Report with Written Opinion corresponding to Interntational Patent Application No. PCT/US2009/040773, dated Feb. 22, 2010. |
| Supplementary European Search Report and Written Opinion corresponding to European Patent Application No. 09701051.6, dated Jan. 19, 2011. |
| Larios et al. (2004) “Synthesis of flavor and fragrance esters using Candida antarctica lipase,” Appl. Microbiol. Biotechnol. 65:373-376. |
| Abdelwahab et al. (2012) “The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma,” PLOS ONE. 7(5):E36197. pp. 1-7. |
| Boyarinov et al. (1984) “Effect of Sodium hydroxybutyrate on myocardial high-energy phosphates, function, and ultrastructure after blood loss”, Biulleten' eksperimental'noĭ biologii i meditsiny. 97(3):289-292. |
| Rossi et al. (2000) “Suppression of Feed Intake after Parenteral Administration of D—β β—Hydroxybutyrate in Pygmy Goats,” J. Vet. Med. A. 47:9-16. |
| Clark et al. (2005) “Dilated Cardiomyopathy and Acute Liver Injury Associated with Combined Use of Ephedra, γ-Hydroxybutyrate, and Anabolic Steroids” Pharmacotherapy. 25(5):756-761. |
| Davey et al. (1988) “Radioprotection of rat subependymal plate with 4-OH sodium butyrate,” NCI Monogr. (6):231-234. |
| Eagles et al. (1997) “The effects of combined treatment with β1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects,” Brit. J. Clinical Pharmacol. 43:291-300. |
| Felig et al. (1971) “Amino acid metabolism in exercising man,” J. Clin. Invest. 50(12):2703-2714. |
| Kohut et al. (1995) “Effects of decresased free fatty acids on fatigue during exercise with carbohydrate feedings,” Medicine and Science in Sports & Exercise. 27(5 Suppl):S102. |
| Kulinskii et al. (1993) “The radioprotective effect of GABA-tropic substances, gamma-hydroxybutyrate and piracetam,” Radiobiologiia. 33(1):133-136.—English Abstract Only. |
| Kashiwaya et al. (2013) “A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease,” Neurobiology of Aging. 34(6):1530-1539. |
| Mori et al. (1987) “New synthesis of both enantiomers of grandisol, the boll weevil pheromon,” Tetrahedron. 43(10):2229-2239. |
| Nair et al. (1988) “Effect of beta-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans,” J. Clin. Invest. 82(1):198-205. |
| Ostrovskaya et al. (1981) “Effect of prolonged administration of sodium hydroxybutyrate on the working capacity and muscle tissue in rats,” Farmakologiya I Toksikologiya. 44(5):534-539.—Only English Abstract Provided. |
| Sherwin et al. (1975) “Effect of ketone infusions on amino acid and nitrogen metabolism in man” J. Clin. Invest. 55(6)1382-1390. |
| Simons et al. (1982) “Long term treatment with Slow Release Oxprenolol Alone, or in Combination with other Drugs: Effects on Blood Pressure, Lipoproteins and Exercise Performance,” Aust. N. Z. J. Med. 12:612-616. |
| Smith et al. (1975) “Initial effect of injury on ketone bodies and other blood metabolites,” Lancet. 1(7897):1-3. |
| Wu et al. (1987) “Ketone bodies inhibit leucine degradationin chick skeletal muscle,” International J. of Biochem. 19(10):937-943. |
| Neubauer et al. (1997) “Myocardial Phosphocreatine-to-ATP Ratio is a predictor of mortality in patients with dilated cardiomyopathy,” Circulation. 96:2190-2196. |
| International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/067027, dated Oct. 30, 2014. |
| International Search Report with Written Opinion corresponding to International Patent Application No. PCT/GB2004/002286, dated Oct. 11, 2004. |
| Search Report corresponding to Great Britain Patent Application No. 1002983.3, dated Jun. 10, 2010. |
| Search Report corresponding to Great Britain Patent Application No. 1304467.2, dated Aug. 23, 2013. |
| Search Report corresponding to Great Britain Patent Application No. 1314127.0, dated Jan. 31, 2014. |
| Search and Examination Report corresponding to Great Britain Patent Application No. 1404400.2, dated Mar. 26, 2014. |
| Search and Examination Report corresponding to Great Britain Patent Application No. 1414016.4, dated Aug. 29, 2014. |
| Search and Examination Report corresponding to Great Britain Patent Application No. 1404577.7, dated Oct. 23, 2014. |
| International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/057250, dated Jun. 11, 2013. |
| International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/068545, dated Jan. 20, 2014. |
| International Search Report corresponding to International Patent Application No. PCT/EP2014/055158, dated Jun. 25, 2014. |
| International Search Report corresponding to International Patent Application No. PCT/EP2013/069189, dated Aug. 12, 2014. |
| Examination Report corresponding to Great Britain Patent Application No. 1404400.2, dated Aug. 18, 2014. |
| Chen et al. (Feb. 2016) “Beta-hydroxybutyrate reduces alcoholic steatohepatits (ASH) via activation of the GPR 109A Receptor,” Proceedings of the American Society for Hematology, 2016. Abstract No. 26. pp. 143-144. |
| Farmer et al. (1973) “Radioprotective Thiazolidines from beta-keto esters,” J. Med. Chem. 16(4):411-413. |
| Baron et al. (1991) “Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow,” J. Clin. Endocrinol. Metab. 73(3):637-643. |
| Boehm et al. (2001) “Increased uncoupling proteins and decreased efficiency in the palmitate-perfused hyperthyroid rat heart,” Am. J. Physiol. Heart Circ. Physiol. 2809(3):H977-H983. |
| Chatham et al. (1999) “Preferential inhibition of lactate oxidation relative to glucose oxidation in the rat heart following diabetes,” Cardiovasc Res. 43(1):96-106. |
| Chatham et al. (2002) “Cardiac carbohydrate metabolism in Zucker diabetic fatty rats,” Cardiovasc Res. 55(1):104-112. |
| Chen et al. (Nov. 13, 2016) “β-hydroxybutyrate protects from alcoholic hepatitis via a GPR109a-C/EBPβ dependent pathway,” AASLD LiverLearning. Abstract No. 1629. Accessible on the Internet at URL: http://liverlearning.aasld.org/aasld/2016/thelivermeeting/144521/yonglin.chen.b-hydroxybutyrate.protects.from.alcoholic.hepatitis.via.a.html. [Last Accessed Apr. 5, 2017]. |
| Cole et al. (2011) “A high fat diet increases mitochondrial fatty acid oxidation and uncoupling to decrease efficiency in rat heart,” Basic Res. Cardiol. 106:447-457. |
| Cox et al. (Oct. 29, 2014) “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extrem. Physiol Med. 3:17. pp. 1-9. |
| Demir et al. (2001) “Serum HbA1c levels and exercise capacity in diabetic patients,” Jpn. Heart J. 42(5):607-616. |
| Estacio et al. (1998) “The association between diabetic complications and exercise capacity in NIDDM patients,” Diabetes Care. 21(2):291-295. |
| Frayn (2003) In; Metabolic Regulation: A Human Perspective. 2nd Ed. Blackwell Science, pp. 94-96. |
| Gangemi “Enhancing Athletic Performance by Predicting Fatigue and Preventing Muscle Failure,” Accessible on the Internet at URL: http://www.drgangemi.com/wp-content/uploads/2011/01/GANGEMI-PREDICTING-FATIGUE-AND-MUSCLE-FAILURE.pdf. [Last Accessed Sep. 20, 2011]. |
| Iozzo et al. (2002) “Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes,” Diabetologia. 45(10):1404-1409. |
| Kemper et al. (Oct. 26, 2015) “An Ester of β-Hydroxybutyrate Regulates Cholesterol Biosynthesis in Rats and a Cholesterol Biomarker in Human,” Lipids. 50(12):1185-1193. |
| Knowler et al. (2002) “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” New Engl. J. Med. 346:393-403. |
| Komiyama et al. (2000) “Near-infrared spectroscopy grades the severity of intermittent claudication in diabetes more accurately than ankle pressure measurement,” British Journal of Surgery. 87(4):459-466. |
| Komiyama et al. (2004) “Effects of a 4-week 70% high carbohydrate / 15% low fat diet on glucose tolerance and on lipid profiles,” Diabetes Res. Clin. Pract. 64(1):11-18. |
| Kwiterovich et al. (2003) “Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children,” JAMA. 290(7):912-920. |
| Lanni et al. (2002) “De Novo Expression of Uncoupling Protein 3 is Associated to Enhanced Mitochondrial Thioesterase-1 Expression and Fatty Acid Metabolism in Liver of Fenofibrate-treated Rats,” FEBS Letters. 525:7-12. |
| Libby et al. (2002) “Diabetic macrovascular disease. The glucose paradox?” Circulation. 106(22):2760-2763. |
| Lodi et al. (1999) “Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study,” Brain. 121(1):121-130. |
| Madsen et al. (1999) “Near-infrared oximetry of the brain,” Prog. Neurobiol. 58(6):541-560. |
| Mahler et al. (1999) “Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment,” J. Clin. Endocrinol. Metab. 84(4):1165-1171. |
| Meyer et al. (1997) “Myocardial blood flow and glucose metabolism in diabetes mellitus,” Am. J. Cardiol. 80(3,Suppl 1):94A-101A. |
| Mori et al. (1984) “Synthesis of the Propionates of (2R, 8R)- and (2S, 8R)-8-methyl-2-decanol, the pheromone of the Western corn rootworm, employing chiral compounds of microbial origin as starting material,” Tetrahedron. 40(2):299-303. |
| Murray et al. (2004) “Uncoupling Proteins in Human Heart,” Lancet. 364:1786-1788. |
| Murray et al. (2005) “Plasma Free Fatty Acids and Peroxisome Proliferator-Activated Receptor a in the Control of Myocardial Uncoupling Protein Levels,” Diabetes. 54(12):3496-3502. |
| Newsholme et al. (1986) In; Biochemistry for the Medical Sciences. John Wiley & Sons. Chichester, U.K. pp. 324-331. |
| Paolisso et al. (1999) “Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease,” Am. J. Cardiol. 83(9):1338-1344. |
| Perez-Jimenez et al. (2001) “A Mediterranean and a high-carbohydrate diet improve glucose metabolism in healthy young persons,” Diabetologia. 44(11):2038-2043. |
| Richieri et al. (1995) “Unbound free fatty acid levels in human serum,” Journal of Lipid Research. 36(2):229-240. |
| Rodrigues et al. (1998) “Metabolic disturbances in diabetic cardiomyopathy,” Molecular and Cellular Biochemistry. 180(1-2):53-57. |
| Sato et al. (1995) “Insulin, ketone bodies, and mitochondria! energy transduction,” Faseb J. 9(8):651-658. |
| Scheuermann-Freestone et al. (2003) “Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes,” Circulation. 107(24):3040-3046. |
| Sidell et al. (2002) “Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart,” Diabetes. 51(4):1110-1117. |
| Smith et al. (2002) “Magnetic Resonance Spectroscopy in Medicine: Clinical Impact,” Progress in Nuclear Magnetic Resonance Spectroscopy. 40:1-34. |
| Stanley et al. (1997) “Regulation of energy substrate metabolism in the diabetic heart,” Cardiovasc. Res. 34(1):25-33. |
| Taegtmeyer et al. (2002) “Adaptation and maladaptation of the heart in diabetes: Part I. General concepts,” Circulation. 105(14):1727-1733. |
| Tinnikov et al. (1999) “Colorimetric micro-determination of free fatty acids in plasma using microplate readers,” Clinica Chemica Acta. 281(1-2):159-162. |
| Toubro et al. (1998) “Twenty-four-hour respiratory quotient: the role of diet and familial resemblance,” J. Clin. Endocrinol. Metabol. 83(8):2758-2764. |
| Tunaru et al. (2003) “PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect,” Nat. Med. 9(3):352-355. |
| Zange et al. (2002) “Creatine Supplementation Results in Elevated Phosphocreatine/Adenosine Triphosphate (ATP) Ratios in the Calf Muscle of Athletes but Not in Patients with Myopathies,” Annals of Neurology. 53(1):126-127. |
| International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/069189, dated Aug. 12, 2014. |
| International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/055158, dated Jun. 25, 2014. |
| Number | Date | Country | |
|---|---|---|---|
| 20140308719 A1 | Oct 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61783167 | Mar 2013 | US |
